A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction

Ana Maciel Afonso, S. Schmiedl, Claudia Becker, S. Tcherny-Lessenot, P. Primatesta, E. Plana, P. Souverein, Y. Wang, J.C. Korevaar, J. Hasford, R. Reynolds, M.C.H. de Groot, R. Schlienger, O. Klungel, M. Rottenkolber

Research output: Contribution to journalSpecial issueAcademicpeer-review

Abstract

Purpose: Results from observational studies on inhaled long-acting beta-2-agonists (LABA) and acute myocardial infarction (AMI) risk are conflicting, presumably due to variation in methodology. We aimed to evaluate the impact of applying a common study protocol on consistency of results in three databases. Methods: In the primary analysis, we included patients from two GP databases (Dutch—Mondriaan, UK—CPRD GOLD) with a diagnosis of asthma and/or COPD and at least one inhaled LABA or a “non-LABA inhaled bronchodilator medication” (short-acting beta-2-agonist or short-/long-acting muscarinic antagonist) prescription between 2002 and 2009. A claims database (USA—Clinformatics) was used for replication. LABA use was divided into current, recent (first 91 days following the end of a treatment episode), and past use (after more than 91 days following the end of a treatment episode). Adjusted hazard ratios (AMI-aHR) and 95 % confidence intervals (95 % CI) were estimated using time-dependent multivariable Cox regression models stratified by recorded diagnoses (asthma, COPD, or both asthma and COPD). Results: For asthma or COPD patients, no statistically significant AMI-aHRs (age- and sex-adjusted) were found in the primary analysis. For patients with both diagnoses, a decreased AMI-aHR was found for current vs. recent LABA use in the CPRD GOLD (0.78; 95 % CI 0.68–0.90) and in Mondriaan (0.55; 95 % CI 0.28–1.08), too. The replication study yielded similar results. Adjusting for concomitant medication use and comorbidities, in addition to age and sex, had little impact on the results. Conclusions: By using a common protocol, we observed similar results in the primary analysis performed in two GP databases and in the replication study in a claims database. Regarding differences between databases, a common protocol facilitates interpreting results due to minimized methodological variations. However, results of multinational comparative observational studies might be affected by bias not fully addressed by a common protocol.
Original languageEnglish
Pages (from-to)1105–1116
Number of pages12
JournalEuropean Journal of Clinical Pharmacology
Volume72
Issue number9
DOIs
Publication statusPublished - Sept 2016

Keywords

  • Acute myocardial infarction
  • Long-acting beta-2-agonists
  • Methodological comparison
  • Secondary data analysis
  • acute heart infarction
  • asthma
  • chronic obstructive lung disease
  • clinical study
  • comorbidity
  • confidence interval
  • controlled study
  • data analysis
  • data base
  • diagnosis
  • disease model
  • exposure
  • hazard ratio
  • human
  • observational study
  • prescription
  • primary medical care
  • proportional hazards model
  • replication study
  • beta 2 adrenergic receptor stimulating agent
  • bronchodilating agent
  • gold
  • muscarinic receptor blocking agent

Fingerprint

Dive into the research topics of 'A methodological comparison of two European primary care databases and replication in a US claims database: inhaled long-acting beta-2-agonists and the risk of acute myocardial infarction'. Together they form a unique fingerprint.

Cite this